ARTICLE SUMMARY:
Vytronus aims to become the Intuitive Surgical of ablation technologies, offering visualization, automation, machine learning, non-contact therapy delivery, and the ability to ablate in any application where catheters are delivered into the bloodstream. Its first application is an enormous one: catheter ablation for atrial fibrillation, where the company aims to boost efficacy rates by offering the first personalized approach.
Atrial fibrillation is a serious medical problem—worst case, AF carries a five-fold risk of stroke. At best, its symptoms, which include feelings of dizziness, shortness of breath, and fatigue, make millions of people highly uncomfortable (33 million people in the world have AF, according to a recent investor presentation by Johnson & Johnson).
